Kristensen, Lars Erik
Alten, Rieke
Puig, Luis
Philipp, Sandra
Kvien, Tore K.
Mangues, Maria Antonia
van den Hoogen, Frank
Pavelka, Karel
Vulto, Arnold G.
Article History
First Online: 29 September 2018
Compliance with Ethical Standards
:
: This article was funded by Biogen International GmbH. Biogen International GmbH provided funding for medical writing support in the development of this paper, and reviewed and provided feedback on the paper to the authors. The authors had full editorial control of the paper, and provided their final approval of all content.All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval regarding the version to be published.
: Lars Kristensen has received grant/research support from UCB, Biogen, Janssen pharmaceuticals, and Novartis, and speakers bureau support from Pfizer, AbbVie, Amgen, UCB, BMS, Biogen, MSD, Novartis, Eli Lilly and Company, and Janssen pharmaceuticals. Rieke Alten has received honoraria from Biogen for advisory board meetings. Luis Puig has received grants/research support from AbbVie, Amgen, Boehringer Ingelheim, Janssen, Lilly, Novartis, Pfizer, Regeneron, Roche, Sanofi, and UCB; has received honoraria or consultation fees from AbbVie, Almirall, Amgen, Baxalta, Biogen, Boehringer Ingelheim, Celgene, Gebro, Janssen, Leo Pharma, Lilly, Merck-Serono, MSD, Novartis, Pfizer, Regeneron, Roche, Sanofi, Sandoz, and UCB; and has participated in a company sponsored speaker’s bureau with Celgene, Janssen, Lilly, MSD, Novartis, and Pfizer. Sandra Philipp has received honoraria for speaker services from AbbVie, Almirall, Amgen, Biogen, Boehringer Ingelheim, BMS GmbH, Lilly, Leo Pharma, Celgene, Hexal, Janssen, MSD, Mundipharma, Novartis and UCB Pharma; advisory board services from AbbVie, Biogen, Eli Lilly, Janssen, Leo Pharma, Pfizer, MSD and Novartis; and investigator services from AbbVie, Almirall, Amgen, Biogen, Boehringer Ingelheim, Celgene, Dermira, Eli Lilly, GSK, Novartis, Pfizer, UCB Pharma and VBL Therapeutics. Tore K. Kvien has received fees for speaking and/or consulting from AbbVie, Biogen, BMS, Boehringer Ingelheim, Celgene, Celltrion, Eli Lilly, Epirus, Hospira, Merck-Serono, MSD, Mundipharma, Novartis, Oktal, Orion Pharma, Hospira/Pfizer, Roche, Sandoz and UCB and received research funding to Diakonhjemmet Hospital from AbbVie, BMS, MSD, Pfizer, Roche and UCB. Maria Antonia Mangues and Frank van den Hoogen have received consultancy fees from Biogen, Celltrion, Mundipharma and Roche. Karel Pavelka has received honoraria for lectures and consultations from AbbVie, Roche, Egis, BMS, MSD, Pfizer, Biogen, UCB, Amgen and Novartis. Arnold G. Vulto has received consulting and speaker’s bureau honoraria from AbbVie, Amgen, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, EGA/Medicines for Europe, Mundipharma, Pfizer/Hospira, Roche, Novartis/Sandoz, Samsung Bioepis, F Hoffmann-La Roche Ltd, Eli Lilly, Febelgen and Hexal/Sandoz Ltd; he is a co-founder and has a societal interest in the Generics & Biosimilar Initiative (GaBI), Biosimilars Initiative, the Netherlands (Chair) and the KU Leuven MABEL research fund.